Given the growing interest in GIP biology, its pleiotropic effects, and the therapeutic applications of incretin analogs, further research is needed to determine whether endogenous GIP, in spite of its short action in circulation before inactivation, may interact with the effects of dual GIP/GLP-1 agonists or triple GIP/GLP-1/glucagon agonists used in obesity (11). Here, GLP1R is linked to obesity disorder.